|
|
- 130+ participants
- In excess of 75 individual organisations represented
- 33 hours of presentations
- Over 10 hours of networking
- 91% of our attendees ranked the congress as good or excellent
- 30 different countries
› Benefits of sponsoring
|
Conference:
Pre-conference workshop
23 Feb 9am - 5pm
Day 1
24 Feb 8.30am - 6:00pm
Day 2
25 Feb 8.30am - 5:30pm
Post-conference workshop
26 Feb 9am - 5pm
Venue:
The Royal Horseguards Hotel, London, United Kingdom
› Email a friend
› Add this to my calendar
|
|
|
|
Day one - Wed 24 Feb 2010 Day one - Wed 24 Feb 2010
8.50am Opening remarks from the chair
Managing Director, Diamond Pharma Services
9am Generic medicines health check – view from the investment community• Changing nature of potential acquirers of generic companies
• Drivers of major pharma interest in generics
• Attractiveness of various markets to potential acquirers
Managing Director, Head EMEA Healthcare, Merrill Lynch International
9.30am The sustainability of healthcare in Europe• Trends and future market environment
• Review of sector enquiry
• Options to improve generic competition
Simon Clark, Vice President, EU Commercial Operations, Teva Pharmaceuticals Europe
10am Challenges for generics in EMEA
10.30am Business model for becoming a successful generic player• Building up a major generics division
• Building up an international business
• Accelerating development of the business
Executive Chairman, Alvogen
11am Speed networking and Morning Tea  Fun high-speed breaks in the conference day
for making new contacts and exchanging details
11.45am Providing affordable, quality medicines to under served
patients• Why Pfizer is turning to multi-source markets for future growth
• How Pfizer will compete in the challenging multi-source space
• Pfizer’s contribution to affordable healthcare strategies
European President, Establish Brands, Pfizer AG
12.15pm Globalisation of Indian generics: entering into the emerging markets through a strategic alliance• Indian generic companies: globalisation and growth
• Changing business models for big pharma and impact on generic companies
• Alliancing as a key strategic driver for growth
Chief Operating Officer & Managing Director, Dr Reddy's Laboratories
12.45pm Hurdles and opportunities for the generic pharmaceutical industry• Factors influencing the generic pharmaceutical business in the next five years
• Sustainability of the generic industry
• Strategic options for mid-sized companies: the key challenges
Director of Development, Gedeon Richter
2.15pm Congressional update and Q&A session on Hatch-Waxman Reforms
2.45pm The European Commission Pharmaceutical Sector Inquiry: final report and follow up• Background on inquiry and main findings
• Policy recommendations
• First enforcement action
Competition Directorate General Director, Basic Industries, Manufacturing and Agriculture, European Commission
3.15pm European Commission's findings on the Pharmaceutical Sector Inquiry: EPO observations and responses• The EPO view on patent-related issues
• How to guarantee high quality standards and accelerated procedures
Principal Director of the Joint Cluster Pure and Applied Organic Chemistry, European Patent Office
4.10pm Opening remarks from PharmaNet chair4.15pm Global review of biosimilar development• Market development over the coming years: what is the opportunity?
• Regulatory developments around the world
• Biosimilars vs. biobetters: what’s the difference and how does it impact strategy?
• How to develop a successful business model
Senior Vice President, Head of Global Biologics, Mylan GmbH
4.45pm Practical overview of clinical development for biosimilars
- Are Biosimilar really just Biogenerics?
- The preclinical requirement for comparability. How does that differ from non-biological generics?
- How different is the clinical development plan of a Biosimilar?
- What are the regulatory hurdles for biosimilars in Europe and the US
- Practical aspects of selecting endpoints – are they different from efficacy studies for new molecules?
- Are the statistical approaches the same as in innovator clinical development?
- Are there particular differences in the safety and pharmacovigilance requirements?
- The spectrum of immunogenicity – Damocles sword or market opportunity?
- Is it possible to extend the number of indications beyond those covered in the clinical trials?
Dr Pablo Fernandez, Senior Vice President, Medical Affairs, PharmaNet Ltd
Senior Vice President, Medical Affairs, PharmaNet Ltd
5.15pm Opportunities and challenges for biosimilar development in China
David Chen, Executive Vice President, Chief Operating Officer, 3SBIO, Inc
5.45pm Closing remarks from the chair7pm Gala dinnerThe gala dinner is an opportunity to relax and network over a few drinks and enjoy great food with your fellow attendees. Also hear a truly inspirational speech from Marc Woods.
 After losing his left leg to cancer at 17, Marc became a member of Great Britain’s Paralympic swimming team and a multiple gold medalist. He has now retired from swimming having competed internationally for 17 years. Marc is also a BBC commentator and author and an ambassador for the London 2012 Olympics. Hear Marc’s inspirational presentation at the networking Gala Dinner after day one. |
|
|
|
|
Robert Wessman
Executive Chairman
Alvogen
Petra Danielsohn-Weil
European President, Established Brands
Pfizer
Satish Reddy
Chief Operating Officer & Managing Director
Dr Reddy's Laboratories
Gerard van Odijk
President & Chief Executive Officer
Teva Pharmaceuticals Europe
Honorable Henry A Waxman
Member of Congress
United States of Americas
|
|
|
|
|
